Mar 28, 2020

Mar 28, 2020

Mar 28, 2020

Model Medicines COVID-19 Drug Development Program Highlighted by FreshBrewedTech

San Diego’s Science & Tech Community on the Front Lines of COVID-19 Innovation

San Diego’s science and tech community is rising to the occasion to help fight the novel coronavirus. Below is a look at several ongoing efforts by local innovative companies, research institutions, and organizations that are developing test kits, vaccines, ventilators, hand sanitizers, real-time dashboards, and more.Model Medicines harnessing the predictive prowess of its AI Drug Discovery Platform to repurpose FDA approved drugs that may serve as a potential therapeutics to prevent individuals from being infected and/or treat individuals infected with the novel coronavirus.

Read More

This article originally appeared on Fresh Brewed Tech, prior to the rebrand of Repurpose.AI to Model Medicines, read the full article here.

Details

Date

Mar 28, 2020

Category

Press

Reading

1 Min

Author

Patrick ONeill

Investor Relations

Related News

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 21, 2025

Announcement

Model Medicines, Icahn School of Medicine at Mount Sinai, and University of California, San Diego Researchers Publish Groundbreaking Preprint on MDL-001, A Broad-Spectrum Antiviral

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases

Jan 14, 2025

Pre-Print

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases